Variables del rendimiento académico.

However, due to the complexity of immunological signaling cascades, extensive

pre-clinical characterization is needed before these potential new drug

candidates can be applied in the clinic.

References

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med.

2005;352:1685-1695.

2. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword.

Nat Rev Immunol. 2006;6:508-519.

3. Hansson GK, Zhou X, Tornquist E, Paulsson G. The role of adaptive immunity in atherosclerosis. Ann N Y Acad Sci. 2000;902:53-62; discussion 62-54.

4. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.

5. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation.

2005;111:3481-3488.

6. Reardon CA, Getz GS. Mouse models of atherosclerosis. Curr Opin Lipidol. 2001;12:167- 173.

7. Zhou X. CD4+ T cells in atherosclerosis. Biomed Pharmacother. 2003;57:287-291. 8. Zhou X, Robertson AK, Rudling M, Parini P, Hansson GK. Lesion development and

response to immunization reveal a complex role for CD4 in atherosclerosis. Circ Res.

2005;96:427-434.

9. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp

Med. 1998;187:129-134.

10. Gao P, Zhou XY, Yashiro-Ohtani Y, Yang YF, Sugimoto N, Ono S, Nakanishi T, Obika S, Imanishi T, Egawa T, Nagasawa T, Fujiwara H, Hamaoka T. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J Leukoc Biol. 2003;73:273-280.

11. Sudano I, Spieker LE, Noll G, Corti R, Weber R, Luscher TF. Cardiovascular disease in HIV infection. Am Heart J. 2006;151:1147-1155.

12. Liu L, Callahan MK, Huang D, Ransohoff RM. Chemokine receptor CXCR3: an unexpected enigma. Curr Top Dev Biol. 2005;68:149-181.

13. Martin-Padura I, Lostaglio S, Schneemann M, Williams L, Romano M, Fruscella P, Panzeri C, Stoppacciaro A, Ruco L, Villa A, Simmons D, Dejana E. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol. 1998;142:117- 127.

14. Ostermann G, Weber KS, Zernecke A, Schroder A, Weber C. JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in transendothelial migration of leukocytes. Nat

Immunol. 2002;3:151-158.

15. Cruikshank WW, Center DM, Nisar N, Wu M, Natke B, Theodore AC, Kornfeld H. Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. Proc Natl Acad Sci U S A. 1994;91:5109-5113. 16. Cruikshank WW, Greenstein JL, Theodore AC, Center DM. Lymphocyte chemoattractant

factor induces CD4-dependent intracytoplasmic signaling in lymphocytes. J Immunol.

1991;146:2928-2934.

17. Cruikshank WW, Kornfeld H, Center DM. Interleukin-16. J Leukoc Biol. 2000;67:757- 766.

18. Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, Lichtman AH. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses.

Proc Natl Acad Sci U S A. 2005;102:1596-1601.

19. Nakai Y, Iwabuchi K, Fujii S, Ishimori N, Dashtsoodol N, Watano K, Mishima T, Iwabuchi C, Tanaka S, Bezbradica JS, Nakayama T, Taniguchi M, Miyake S, Yamamura T, Kitabatake A, Joyce S, Van Kaer L, Onoe K. Natural killer T cells accelerate atherogenesis in mice. Blood. 2004;104:2051-2059.

20. Tupin E, Nicoletti A, Elhage R, Rudling M, Ljunggren HG, Hansson GK, Berne GP. CD1d- dependent activation of NKT cells aggravates atherosclerosis. J Exp Med. 2004;199:417- 422.

21. Kotani A, Ishikawa T, Matsumura Y, Ichinohe T, Ohno H, Hori T, Uchiyama T. Correlation of peripheral blood OX40+(CD134+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation.

Blood. 2001;98:3162-3164.

22. Weinberg AD, Wegmann KW, Funatake C, Whitham RH. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol. 1999;162:1818-1826.

23. Sasson SC, Zaunders JJ, Kelleher AD. The IL-7/IL-7 receptor axis: understanding its central role in T-cell homeostasis and the challenges facing its utilization as a novel therapy. Curr Drug Targets. 2006;7:1571-1582.

24. Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A. 1999;96:6873-6878.

25. Christensen JE, de Lemos C, Moos T, Christensen JP, Thomsen AR. CXCL10 is the key ligand for CXCR3 on CD8+ effector T cells involved in immune surveillance of the lymphocytic choriomeningitis virus-infected central nervous system. J Immunol.

2006;176:4235-4243.

26. Hokeness KL, Deweerd ES, Munks MW, Lewis CA, Gladue RP, Salazar-Mather TP. CXCR3-dependent recruitment of antigen-specific T lymphocytes to the liver during murine cytomegalovirus infection. J Virol. 2007;81:1241-1250.

27. Zhong MX, Kuziel WA, Pamer EG, Serbina NV. Chemokine receptor 5 is dispensable for innate and adaptive immune responses to Listeria monocytogenes infection. Infect

Immun. 2004;72:1057-1064.

28. Weber C. Killing two birds with one stone: targeting chemokine receptors in atherosclerosis and HIV infection. Arterioscler Thromb Vasc Biol. 2005;25:2448-2450. 29. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD,

Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018-1028.